Email: cspc@cspc.cn
News
News Center
Apr. 11
2025
SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr. 08
JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar. 21
SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 18
JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Mar. 13
SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar. 05
JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
